Ads
related to: toxic erythema of chemotherapy treatment- Dosing
Learn About Dosing
And Administration.
- Explore Real Case Studies
See How A Key Opinion Leader
Treated Their Patient.
- Dosing
Search results
Results From The WOW.Com Content Network
Chemotherapy-induced acral erythema, also known as palmar-plantar erythrodysesthesia or hand-foot syndrome is reddening, swelling, numbness and desquamation (skin sloughing or peeling) on palms of the hands and soles of the feet (and, occasionally, on the knees, elbows, and elsewhere) that can occur after chemotherapy in patients with cancer.
There are a number of strategies in the administration of chemotherapeutic drugs used today. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent.
NEH is self-limited and usually resolves without treatment. In the overwhelming majority of the cases, spontaneous resolution occurs within 1–2 weeks. However, if the patient developed NEH after chemotherapy, the offending cytotoxic drug has to be discontinued, and the patient must avoid this particular cytotoxic drug in the future, because ...
Myelosupression, embryo-fetal toxicity, hepatotoxicity (rare) [19] Trabectedin: IV Alkylates DNA. Advanced liposarcoma and leimyosarcoma Bone marrow suppression, rhabdomyolysis, embryo-fetal toxicity, capillary leak syndrome, hepatotoxicity [20] 1.10 Platinum compounds: Carboplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific.
Chemotherapy-induced acral erythema ... (erythema toxicum, toxic erythema of the ... are skin conditions of the palms and soles which are resistant to treatment. [34]
Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. [3]: 129 These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome.
The next year the Chicago group, led by Leon O. Jacobson, conducted trials with HN2 (chlormethine) which was the only agent in this group to see eventual clinical use. Wartime secrecy prevented any of this ground-breaking work on chemotherapy from being published, but papers were released once wartime secrecy ended, in 1946. [24]
Chemotherapy-induced peripheral neuropathy (CIPN) is a nerve-damaging side effect of antineoplastic agents in the common cancer treatment, chemotherapy. [1] CIPN afflicts between 30% and 40% of patients undergoing chemotherapy.